Bavarian Nordic files patent infringement suit against Oxford BioMedica

Bavarian Nordic has filed a patent infringement suit against Oxford
BioMedica plc, Biomedica, Inc., and Oxford BioMedica Ltd., in the
United States District Court of the Southern District of California.

Bavarian Nordic owns several United States patents relating to an
attenuated strain of the company's core technology, MVA-BN®, which is
the basis for its innovative smallpox vaccine, IMVAMUNE®. MVA-BN®
also holds promise as a vector for delivering recombinant vaccines.

Bavarian Nordic asserts three patents as a basis for its infringement
action, which are U.S. Patent No. 6,761,893, U.S. Patent No.
6,913,752 and U.S. Patent No. 7,335,364.

The claim in this case is that the defendants have infringed Bavarian
Nordic's patents by commercializing the patented technology in ways
that have yielded large payments from Sanofi-Aventis under the
agreement between them for the development and commercialization of
TroVax®.

The legal action versus Oxford BioMedica does not change Bavarian
Nordic's previous announced financial guidance for 2008.

Anders Hedegaard, President & CEO of Bavaran Nordic, said: "The
initiation of this infringement action is a necessary step to enforce
our intellectual property rights. We have built a strong patent
portfolio on the MVA technology, which we seek to utilize to expand
and support our business through licensing agreements. However if
these cannot be obtained, we will vigorously defend our IP position
to prevent infringement."



Kvistgård, 30 June 2008


Asger Aamund
Chairman



Contact: Anders Hedegaard, President & CEO | +45 23 20 30 64